cut-off levels between the 25% and 75% quartile using the log-rank test determined that median value (721.3 cm 3 ) as the cut-off point yielded the highest difference in progression-free survival (PFS) and overall survival (OS), which was used as cut-off level in statistical analysis. Therefore, two SV groups (high SV group and low SV group) were separated according to the median value. The baseline characteristics (age, sex, median absolute lymphocyte count, median beta-2-microglobulin, median lactate dehydrogenase level and bone marrow infiltration pattern) were compatible between the high SV group and the low SV group. The low SV group was associated with longer PFS and OS than the high SV group (P < 0.001, P < 0.001; Figure 1 ). The high SV (SV ‡ 721.3 cm 3 ) was associated with poorer response (SV between complete response and partial response (PR), P = 0.075; PR and stable disease (SD), P = 0.366; SD and PD, P = 0.019; Figure 1C ) and higher Rai stage (SV between Rai II and III, P = 0.005; Rai III and IV, P = 0.026; Figure 1D ). The result shows that the assessment of tumor volume using imaging technique can be an important predictive factor of prognosis as well as disease progression in CLL patients.
The present study is the first attempt whether the clinical importance of three-dimensional reconstruction of tumor burden using imaging technique is useful in clinical practice. A further well-designed, large clinical study is warranted to confirm the results including fludarabine or rituximab. Clinical outcome according to the splenic volume (SV) measured by computed tomography (CT) and correlation between SV by CT and response or Rai stage. Low SV group was associated with longer progression-free survival and overall survival than high SV group (P < 0.001, P < 0.001). SVs in PD were higher than those in stable disease (SD) group, while differences of SVs in other response groups were not significant (SVs between complete response and partial response (PR), P = 0.075; PR and SD, P = 0.366; SD and PD, P = 0.019). SVs in Rai stage IV was higher than other Rai stage (P < 0.001). SVs in each Rai stage were significantly different (difference of SVs between RAI II and III, P = 0.005; the difference between RAI III and IV, P = 0.026).
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